278 related articles for article (PubMed ID: 28541488)
1. The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade.
Schurich A; Raine C; Morris V; Ciurtin C
Rheumatology (Oxford); 2018 Feb; 57(2):246-254. PubMed ID: 28541488
[TBL] [Abstract][Full Text] [Related]
2. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
Gandhi M; Alwawi E; Gordon KB
Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
Ergen EN; Yusuf N
Exp Dermatol; 2018 Jul; 27(7):737-747. PubMed ID: 29704872
[TBL] [Abstract][Full Text] [Related]
4. From bench to bedside--translational research in psoriasis.
Prinz JC
J Eur Acad Dermatol Venereol; 2010 Oct; 24 Suppl 6():1-4. PubMed ID: 20831702
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.
Johnsson HJ; McInnes IB
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S115-8. PubMed ID: 26471946
[TBL] [Abstract][Full Text] [Related]
6. Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis.
Martin R
Lancet Neurol; 2008 Sep; 7(9):765-6. PubMed ID: 18702995
[No Abstract] [Full Text] [Related]
7. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
[TBL] [Abstract][Full Text] [Related]
8. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
Mortel MR; Emer J
J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145
[TBL] [Abstract][Full Text] [Related]
9. Briakinumab for the treatment of plaque psoriasis.
Traczewski P; Rudnicka L
BioDrugs; 2012 Feb; 26(1):9-20. PubMed ID: 22077474
[TBL] [Abstract][Full Text] [Related]
10. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
11. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.
Teng MW; Bowman EP; McElwee JJ; Smyth MJ; Casanova JL; Cooper AM; Cua DJ
Nat Med; 2015 Jul; 21(7):719-29. PubMed ID: 26121196
[TBL] [Abstract][Full Text] [Related]
12. IL-12-and IL-23 in health and disease.
Croxford AL; Kulig P; Becher B
Cytokine Growth Factor Rev; 2014 Aug; 25(4):415-21. PubMed ID: 25130295
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.
Frieder J; Kivelevitch D; Haugh I; Watson I; Menter A
Clin Pharmacol Ther; 2018 Jan; 103(1):88-101. PubMed ID: 28960267
[TBL] [Abstract][Full Text] [Related]
14. Briakinumab.
Lima XT; Abuabara K; Kimball AB; Lima HC
Expert Opin Biol Ther; 2009 Aug; 9(8):1107-13. PubMed ID: 19569977
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
[TBL] [Abstract][Full Text] [Related]
16. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
Benson JM; Peritt D; Scallon BJ; Heavner GA; Shealy DJ; Giles-Komar JM; Mascelli MA
MAbs; 2011; 3(6):535-45. PubMed ID: 22123062
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab poised to enter the psoriasis market.
Schmidt C
Nat Biotechnol; 2008 Dec; 26(12):1317-8. PubMed ID: 19060851
[No Abstract] [Full Text] [Related]
18. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
19. The role of IL 23 in the treatment of psoriasis.
Puig L
Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
[TBL] [Abstract][Full Text] [Related]
20. Novel biologic therapies in development targeting IL-12/IL-23.
van de Kerkhof PC
J Eur Acad Dermatol Venereol; 2010 Oct; 24 Suppl 6():5-9. PubMed ID: 20831703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
